Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study
Paper cited by one trial page, indexed on Europe PMC as PubMed record 38564684 and published in JCO Precision Oncology; the citing page links this DOI, which is how the record was matched.
Overview
Purpose: With the advent of precision medicine, molecular tumor boards (MTBs) were established to interpret genomic results and guide decision making for targeted therapy in oncology patients. There are currently no universal guidelines for how MTBs should operate and thus variance can be seen depending on which MTB is reviewing the case. This study assesses the concordance of MTB recommendations when a participant case is reviewed by two different MTBs, establishes potential reasons for discordance, and advocates for the establishment of standard MTB operating guidelines.
Patients and methods: Participants with advanced cancer, who had exhausted all standard treatment options were screened for the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cases were submitted for MTB review if the treatment proposal was outside the protocol genomic matching rules, or if multiple treatment options were identified. Of the 306 cases submitted for review by the TAPUR MTB from 2016 to 2018, 107 were randomly selected for secondary review by a different MTB group. Recommendations from the original review were not disclosed. Concordance between MTB group recommendations was assessed. Concordance was defined as agreement between MTB reviews on the genomic alteration and study drug match proposed by the clinical site. Thematic qualitative analysis was conducted for the discordant cases to assess reasons for discordance.
Results: Complete or partial concordance was observed in 79% of cases (95% CI, 70 to 86; one-sided P =.25). Most discordant analyses were due to disagreements on the strength of evidence regarding efficacy of the proposed treatment (32%).
Conclusion: When presented with identical participant cases, different MTB review groups make the same or similar treatment recommendations approximately 80% of the time.
Indexed on Europe PMC as PubMed record 38564684 (DOI 10.1200/po.23.00615). Matched by DOI alone: one trial page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- Key paperPalbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Shares JCO Precision Oncology, TAPUR (Targeted Agent and Profiling Utilization Registry).
- Key paperPertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study
Shares JCO Precision Oncology, TAPUR (Targeted Agent and Profiling Utilization Registry).